ABSTRACT
INTRODUCTION
Immunotoxins are widely used to eliminate specific cell populations in vitro and in vivo for both basic research and pharmaceutical development. Immunotoxins are frequently cited in the neurosciences, where immunolesioning agents can be constructed from antibodies to specific cell types for the study of behavior (8) . 192 IgG-SAP is the most specific and potent lesioning agent available for the cholinergic neurons of the basal forebrain (9) , and reports of its use have appeared in over 100 publications. Immunotoxins may also have therapeutic applications: an anti CD-7-SAP immunotoxin is in preclinical development for the treatment of leukemia (4), for example.
The creation of an immunotoxin is a long and costly process. An antibody to the antigen of choice must be produced, and the performance of the antibody as part of an immunotoxin must be evaluated. Desirable traits of an immunotoxin antibody include high specificity and rapid internalization. The choice of the correct antibody is crucial to the performance of an immunotoxin because a well-chosen antibody allows the complete elimination of a specific cell population with no nonspecific killing. If the antibody is to be conjugated to the toxin, both the unconjugated antibody and the free toxin must be purified away from the conjugate. Screening large numbers of antibodies for immunotoxin capabilities in this manner would be prohibitively expensive in both cost and time. The ability to perform a primary screen before conjugation and purification is a great advantage in the creation of an immunotoxin. Weltman et al. reported on a ricin-based second immunotoxin for screening monoclonal antibodies to tumor associated antigens (7) .
Advanced Targeting Systems has created a second immunotoxin that is a useful tool for screening antibodies as potential immunotoxins. Called Mab-ZAP, this second immunotoxin is a goat anti-mouse polyclonal anti-IgG antibody that is conjugated to saporin, the most potent of the plant ribosome-inactivating proteins (5) . Saporin induces cell death by apoptosis (1) . The mechanism of action of Mab-ZAP is detailed in Figure 1 . Use of a second immunotoxin eliminates the time-consuming and expensive step of conjugating each candidate antibody to the toxin: it can simply be added to cells in culture conditions together with the antibody of interest. Mab-ZAP allows a large number of antibodies to be screened quickly and efficiently or individual monoclonals to be evaluated for efficacy for use in an immunotoxin.
MATERIALS AND METHODS
These experiments are designed to demonstrate the specificity and function of Mab-ZAP and also show that Mab-ZAP will not be internalized easily by cells unless a primary anti -body is present. IgG are administered to cells in culture both singly and together, and elimination of cells is measured. The results are also compared to the proven conjugate 192 IgG-SAP (Advanced Targeting Systems, San Diego, CA, USA).
Cells
C6 cells, a rat glioma cell line shown to express p75 (10), were obtained from ATCC (Manassas, VA, USA) and singlecell cloned for sensitivity to 192 IgG-SAP, creating cell line C6/9. Cells are maintained in F12K medium with 2 mM Lglutamine, 15% horse serum, 2.5% FBS, 1.5 g/L sodium bicarbonate and penicillin-streptomycin.
Antibodies and Immunotoxins
Mab-ZAP is a goat anti-mouse IgG covalently linked to saporin, a ribosome-inactivating protein (RIP) from the seeds of the plant Saponaria officinalis (3, 6) . 192 IgG is a mouse monoclonal antibody to the rat low-affinity nerve growth factor receptor, also known as p75 (2) . Xpress ™ antibody, a mouse monoclonal antibody to an N-terminal tag used in protein expression in the Xpress system was a gift from M. Bergseid (Invitrogen, Carlsbad, CA, USA).
Cytotoxicity Assay
We prepared 96-well microplates (Corning, Corning, NY, USA) by plating C6/9 cells at 2500 cells/90 µ L/well. The plates are incubated 16 h at 37°C in the presence of 5% CO 2 . The medium used is F12K that contains 2 mM L-glutamine, 15% horse serum, 2.5% FBS, 1.5 g/L sodium bicarbonate and penicillin-streptomycin.
Antibodies and Mab-ZAP are added in a volume of 10 µ L, bringing the well volume to 100 µ L. The plates are incubated 96 h at 37°C in the presence of 5% CO 2 . For each plate, 75 µ L phenazine methosulfate (0.92 mg/mL in Dulbecco's PBS) are added to 1.5 mL (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymet hoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS, 2 mg/mL in Dulbecco's PBS [both from Promega, Madison, WI, USA]), and 20 µ L are added to each well. The plates are incubated 1 h at 37°C in the presence of 5% CO 2 .
The plates are read at 492 nm in a Spectra Max 340 ® and data analyzed using SOFTmax PRO 2.2.1 ® (both from Molecular Devices, Sunnyvale, CA, USA) and GraphPad Prism™ (GraphPad, San Diego, CA, USA). A 4-parameter curve is generated using concentration and percent of control cells surviving, and the concentration of primary antibody at which the antibody + Mab-ZAP complex eliminates fifty percent of the cells (ED 50 ) is calculated from that curve.
RESULTS
First, a competitive assay demonstrates that the ability of Mab-ZAP in conjunction with 192 IgG to eliminate C6/9 cells is comparable to 192 IgG-SAP. To avoid 192 IgG binding to p75 positive cells and internalizing before complexing, Mab-ZAP is always added to the wells first. Another alternative is to preincubate Mab-ZAP and 192 IgG together before adding them to the wells. Sequential addition was chosen because it is much more efficient than preincubation for screening large numbers of primary antibodies. As seen in Figure 2 , although the ED 50 s listed in the table for Mab-ZAP + 192 IgG are quite similar for the three concentrations of Mab-ZAP assayed, the curve generated by 50 ng/well most closely approximates that generated by 192 IgG-SAP. The ED 50 s in Figure 2 also show that Mab-ZAP + 192 IgG is three to fourfold less effective than the directly conjugated 192 IgG-SAP.
The curve generated with 10 ng/well Mab-ZAP demonstrates that the elimination effect is diluted out by excess levels of free primary antibody (Figure 2 By itself, Mab-ZAP is not internalized at working concentrations. This fact is significant because no activation is necessary for the Mab-ZAP molecule to stop protein synthesis, only internalization so that the RIP (saporin) has access to the cellular ribosomes. As shown in Figure 3 Figure 4 shows that the Xpress antibody does compete away Mab-ZAP from 192 IgG; at 1000 ng/well of Xpress antibody, the cell population returns to 78% of control. This result is compared to 100 pM 192 IgG + 50 ng/well Mab-ZAP without Xpress antibody, which eliminates >50% of the cell population, as shown in Figure 2 .
The final step is to demonstrate the effect of varying the Mab-ZAP concentration in the presence of a constant concentration of 192 IgG. Figure 5 shows the effect when Mab-ZAP is diluted out against several concentrations of 192 IgG. As the Mab-ZAP concentration reaches 1 ng/well, surviving cells approach 100%. These data reinforce the data from Figure 2 
DISCUSSION
The usefulness of immunotoxins as research reagents and therapeutics is widely recognized, but efficient use of this technology requires an effective screening process. In these experiments, the effectiveness of the second immunotoxin, Mab-ZAP, as a valuable tool for screening is demonstrated. A second immunotoxin demonstrates a candidate antibody's binding and internalization characteristics. It also facilitates narrowing down the number of antibody candidates for immunotoxins, which allows a concentration of time and effort on those antibodies that have the characteristics necessary to make an effective immunotoxin: specificity and internalization.
